Cargando…
Aberrant RNA splicing and therapeutic opportunities in cancers
There has been accumulating evidence that RNA splicing is frequently dysregulated in a variety of cancers and that hotspot mutations affecting key splicing factors, SF3B1, SRSF2 and U2AF1, are commonly enriched across cancers, strongly suggesting that aberrant RNA splicing is a new class of hallmark...
Autores principales: | Yamauchi, Hirofumi, Nishimura, Kazuki, Yoshimi, Akihide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819303/ https://www.ncbi.nlm.nih.gov/pubmed/34812550 http://dx.doi.org/10.1111/cas.15213 |
Ejemplares similares
-
Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer
por: Kitamura, Koji, et al.
Publicado: (2021) -
Aberrant Sialylation in Cancer: Therapeutic Opportunities
por: Munkley, Jennifer
Publicado: (2022) -
Aberrant RNA Splicing in Cancer and Drug Resistance
por: Wang, Bi-Dar, et al.
Publicado: (2018) -
Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities
por: Blijlevens, Maxime, et al.
Publicado: (2021) -
Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
por: Dou, Zhihui, et al.
Publicado: (2021)